Myxedema Coma or Crisis: Practice Essentials, Background, Pathophysiology

Admin
The term myxedema has been applied to several clinical entities and is often used interchangeably with severe hypothyroidism, the common clinical condition in which the thyroid gland produces abnormally low levels of hormones. Myxedema also refers to 2 different dermatologic conditions.

Overview

Practice Essentials

Myxedema is a term generally used to denote severe hypothyroidism. Myxedema coma, occasionally called myxedema crisis, is a rare, life-threatening clinical condition that consists of severe hypothyroidism with decompensation. The disorder most often occurs in patients with long-standing, undiagnosed hypothyroidism and is typically precipitated by a systemic illness. Patients with myxedema coma are usually severely ill, with significant hypothermia and depressed mental status. [1, 2]

Myxedema coma is a medical emergency that must be attended to right away. If the diagnosis is suspected, immediate management is necessary before confirming the diagnosis due to the high associated mortality rate. Patients with myxedema coma should be treated in an intensive care unit (ICU) with continuous cardiac monitoring. Initial steps in therapy include supportive measures, thyroid hormone replacement, and glucocorticoid therapy (until adrenal insufficiency is excluded).

Signs and symptoms

The following features may be present:

  • Hypothermia

  • Hypotension

  • Decreased pulse pressure, normal systolic pressure, elevated diastolic pressure, slow pulse

  • Periorbital edema, swelling of the face and lips, thickened nose, enlarged tongue (macroglossia), enlarged tonsils, coarse or thin hair

  • The thyroid is generally small or nonpalpable; however, it can be enlarged

  • Slow respiratory rate, hypoventilation, congestion, pleural effusion

  • Soft or distant heart sounds, diminished apical impulse, bradycardia, enlarged heart, pericardial effusion

  • Abdominal distention due to ileus or ascites; diminished or absent bowel sounds

  • Urinary bladder distention

  • Cold extremities

  • Non-pitting edema of the hands and feet

  • Cool, pale, dry, scaly, and thickened skin; ecchymoses; purpura

  • Dry, brittle nails

  • Confusion, stupor, obtundation, or coma; slow speech; seizures; reflexes with a slow relaxation phase

Workup

Laboratory studies include the following:

  • Thyroid-stimulating hormone (TSH) and free thyroxine (T4) levels

  • Serum electrolytes and serum osmolality - Hyponatremia with low serum osmolality is common

  • Serum creatinine - Usually elevated

  • Serum glucose - Hypoglycemia is common, but this may also suggest concomitant adrenal insufficiency

  • Complete blood count (CBC) - Leukocytosis is not common; bands and/or a left shift may be the only signs of infection

  • Arterial blood gases - Increased partial pressure of CO2 (PCO2) and decreased partial pressure of oxygen (PO2) are usually found

  • Cultures for sepsis - Blood cultures and others (such as urine and sputum) as indicated

Imaging studies include chest radiographs, computed tomography (CT) scans of the brain, and other studies, as dictated by the patient’s condition.

Electrocardiographic findings may include the following:

  • Sinus bradycardia

  • Variable degrees of heart block

  • Low-amplitude QRS complexes

  • Nonspecific ST-segment changes

  • Flattened or inverted T waves

  • Prolonged QT intervals

  • Ventricular arrhythmias

Management

Thyroid therapy

Because of the rarity of myxedema coma, randomized trials comparing different treatment modalities are not available. There is no agreement on the type of thyroid hormone preparation to prescribe (levothyroxine [T4] alone, liothyronine [T3] alone, or T4 and T3 combined), or on the dose, frequency, and route of administration.

Because gastrointestinal absorption may be compromised, IV thyroid therapy is initially advised. T3 has a quicker onset of action and greater biologic activity than T4. In addition, the conversion of T4 to T3 is usually impaired in hypothyroidism and in the setting of severe systemic illness.

We suggest the administration of both T4 and T3 in the treatment of myxedema coma.

Glucocorticoid therapy

Patients with myxedema coma can have concomitant primary adrenal insufficiency, while patients with secondary hypothyroidism may have associated secondary adrenal insufficiency. Glucocorticoids should be administered until the possibility of adrenal insufficiency is excluded.

eMedicine Logo

Background

Myxedema is a clinical state of severe thyroid hormone deficiency that results in the failure of multiple organs. [3, 4, 5, 6]  The term myxedema is also used to describe the dermatologic changes that occur in hypothyroidism and occasionally in hyperthyroidism; myxedema refers specifically, in these cases, to the dermal deposition of mucopolysaccharides, which causes the affected area to swell. When skin changes occur in hyperthyroidism, most commonly Graves disease, the disorder is called pretibial myxedema.  

Myxedema coma typically occurs in patients with long-lasting, previously undiagnosed hypothyroidism and is generally precipitated by infection, congestive heart failure, acute myocardial infarction, cerebrovascular accident, gastrointestinal bleeding, or medications. [7, 8, 9, 10, 11, 12]

eMedicine Logo

Pathophysiology

Myxedema coma occurs because of long-standing, undiagnosed or undertreated hypothyroidism. Although any of the causes of hypothyroidism can lead to myxedema coma, the most common is chronic autoimmune thyroiditis. It can also occur in patients who had a thyroidectomy or who underwent radioactive iodine therapy for hyperthyroidism. Rare causes of myxedema coma include secondary hypothyroidism and medications such as lithium and amiodarone.

Given the importance of thyroid hormones in cell metabolism, long-standing hypothyroidism is associated with a reduced metabolic rate and decreased oxygen consumption, affecting all body systems. [13]  Consequently, myxedema coma can also result when a hypothyroidism-induced decrease in drug metabolism leads to overdosing of medications, including sedatives, hypnotics, and anesthetic agents.

eMedicine Logo

Epidemiology

United States

Hypothyroidism is one of the most common endocrine disorders, affecting 11.7% of the US population. [14]  However, myxedema coma is rare (with the precise prevalence unknown), likely due to the common availability thyroid function testing and, therefore, the widespread early detection of hypothyroidism.

International

In areas where there is an adequate intake of iodine, the most common cause of hypothyroidism is autoimmune thyroid disease, with a prevalence that varies from 5.6% to 11.4%. [15]  In regions where inadequate amounts of iodine are ingested, the most common cause of hypothyroidism is iodine deficiency. Severe hypothyroidism is observed only with severe iodine deficiency, which is generally found in isolated, mountainous regions of South America, Africa, and Asia. An observational study showed that the estimated incidence of myxedema coma in Japan was 1.08 per million people per year. [16]

eMedicine Logo

Prognosis

Myxedema coma is a medical emergency. If the condition is not promptly diagnosed and treated, the mortality rate can be as high as 50%. Even with immediate recognition and appropriate medical intervention, mortality rates of up to 25% have been observed. [17, 18, 19]

Factors associated with poor prognosis are body temperature less than 93°F (33.9°C), persistent hypothermia unresponsive to 72 hours of therapy, advanced age, bradycardia (< 44 beats per minute), sepsis, myocardial infarction, and hypotension. In addition, the patient's level of consciousness and scores on the Glasgow Coma Scale and the Acute Physiology and Chronic Health Evaluation (APACHE) II have been found to be most predictive of survival. [19, 20]

eMedicine Logo

Patient Education

Patients who are diagnosed with hypothyroidism should be counseled regarding the necessity of taking daily thyroid hormone replacement and monitoring of thyroid tests on a regular basis.

Patients with a history of thyroiditis or who have undergone thyroid irradiation or thyroid surgery should be counseled that hypothyroidism might occur in the future. They should be educated about the symptoms of hypothyroidism and should understand the importance of seeking timely medical advice for examination and testing. 

eMedicine Logo

  1. Elshimy G, Chippa V, Correa R. Myxedema. StatPearls. 2023 Aug 14. [QxMD MEDLINE Link]. [Full Text].

  2. Bourcier S, Coutrot M, Ferre A, et al. Critically ill severe hypothyroidism: a retrospective multicenter cohort study. Ann Intensive Care. 2023 Mar 9. 13 (1):15. [QxMD MEDLINE Link]. [Full Text].

  3. Wall CR. Myxedema coma: diagnosis and treatment. Am Fam Physician. 2000 Dec 1. 62 (11):2485-90. [QxMD MEDLINE Link]. [Full Text].

  4. Fliers E, Wiersinga WM. Myxedema coma. Rev Endocr Metab Disord. 2003 May. 4 (2):137-41. [QxMD MEDLINE Link].

  5. Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007 Jul-Aug. 22 (4):224-31. [QxMD MEDLINE Link].

  6. Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am. 2012 Mar. 96 (2):385-403. [QxMD MEDLINE Link].

  7. Rehman SU, Cope DW, Senseney AD, Brzezinski W. Thyroid disorders in elderly patients. South Med J. 2005 May. 98 (5):543-9. [QxMD MEDLINE Link].

  8. Yafit D, Carmel-Neiderman NN, Levy N, et al. Postoperative myxedema coma in patients undergoing major surgery: Case series. Auris Nasus Larynx. 2019 Aug. 46 (4):605-8. [QxMD MEDLINE Link].

  9. Santiago R, Rashkin MC. Lithium toxicity and myxedema coma in an elderly woman. J Emerg Med. 1990 Jan-Feb. 8 (1):63-6. [QxMD MEDLINE Link].

  10. Agarwal V, Parikh V, Otterbeck PE, Lafferty J. Myxedema coma induced by short-term amiodarone therapy. Am J Med Sci. 2014 Mar. 347 (3):258-9. [QxMD MEDLINE Link]. [Full Text].

  11. Hawatmeh A, Thawabi M, Abuarqoub A, Shamoon F. Amiodarone induced myxedema coma: Two case reports and literature review. Heart Lung. 2018 Jul-Aug. 47 (4):429-31. [QxMD MEDLINE Link].

  12. Gummalla S, Manjunath M, Phillips B. Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab. Case Rep Endocrinol. 2020. 2020:8855943. [QxMD MEDLINE Link]. [Full Text].

  13. Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993 Jun. 22 (2):279-90. [QxMD MEDLINE Link].

  14. Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism Prevalence in the United States: A Retrospective Study Combining National Health and Nutrition Examination Survey and Claims Data, 2009-2019. J Endocr Soc. 2022 Nov 17. 7 (1):bvac172. [QxMD MEDLINE Link]. [Full Text].

  15. Hu X, Chen Y, Shen Y, Tian R, Sheng Y, Que H. Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A systematic review and meta-analysis. Front Public Health. 2022. 10:1020709. [QxMD MEDLINE Link]. [Full Text].

  16. Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. J Epidemiol. 2017 Mar. 27 (3):117-22. [QxMD MEDLINE Link]. [Full Text].

  17. Wartofsky L. Myxedema coma. Endocrinol Metab Clin North Am. 2006 Dec. 35 (4):687-98, vii-viii. [QxMD MEDLINE Link].

  18. Dutta P, Bhansali A, Masoodi SR, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008. 12 (1):R1. [QxMD MEDLINE Link]. [Full Text].

  19. Mathew V, Misgar RA, Ghosh S, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011. 2011:493462. [QxMD MEDLINE Link]. [Full Text].

  20. Rodriguez I, Fluiters E, Perez-Mendez LF, Luna R, Paramo C, Garcia-Mayor RV. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. 2004 Feb. 180 (2):347-50. [QxMD MEDLINE Link]. [Full Text].

  21. Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 1990 Jun. 88 (6):631-7. [QxMD MEDLINE Link].

  22. Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007 Jul-Aug. 22 (4):224-31. [QxMD MEDLINE Link].

  23. Westphal SA. Unusual presentations of hypothyroidism. Am J Med Sci. 1997 Nov. 314 (5):333-7. [QxMD MEDLINE Link].

  24. Mavroson MM, Patel N, Akker E. Myxedema Psychosis in a Patient With Undiagnosed Hashimoto Thyroiditis. J Am Osteopath Assoc. 2017 Jan 1. 117 (1):50-4. [QxMD MEDLINE Link]. [Full Text].

  25. Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV. Ventilatory control in myxedema and hypothyroidism. N Engl J Med. 1975 Mar 27. 292 (13):662-5. [QxMD MEDLINE Link].

  26. Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med. 1988 May. 84 (5):877-83. [QxMD MEDLINE Link].

  27. Lee CH, Wira CR. Severe angioedema in myxedema coma: a difficult airway in a rare endocrine emergency. Am J Emerg Med. 2009 Oct. 27 (8):1021.e1-2. [QxMD MEDLINE Link].

  28. Ji JS, Chae HS, Cho YS, et al. Myxedema ascites: case report and literature review. J Korean Med Sci. 2006 Aug. 21 (4):761-4. [QxMD MEDLINE Link]. [Full Text].

  29. Fukunaga K. Refractory gastrointestinal bleeding treated with thyroid hormone replacement. J Clin Gastroenterol. 2001 Aug. 33 (2):145-7. [QxMD MEDLINE Link].

  30. Chiong YV, Bammerlin E, Mariash CN. Development of an objective tool for the diagnosis of myxedema coma. Transl Res. 2015 Sep. 166 (3):233-43. [QxMD MEDLINE Link]. [Full Text].

  31. Borzì AM, Biondi A, Basile F, Vacante M. Diagnosis and treatment of hypothyroidism in old people : A new old challenge. Wien Klin Wochenschr. 2020 Mar. 132 (5-6):161-7. [QxMD MEDLINE Link].

  32. Chaudhari D, Gangadharan V, Forrest T. Heart failure presenting as myxedema coma: case report and review article. Tenn Med. 2014 Feb. 107 (2):39-41. [QxMD MEDLINE Link].

Previous

Next

Author

Mohsen S Eledrisi, MD, FACP, FACE Senior Consultant, Department of Medicine/Endocrinology, Hamad Medical Corporation, Qatar

Mohsen S Eledrisi, MD, FACP, FACE is a member of the following medical societies: American Association of Clinical Endocrinology, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Romesh Khardori, MD, PhD, FACP (Retired) Professor, Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinology, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for Physician Leadership, American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society, International Society for Clinical Densitometry, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Stephanie L Lee, MD, PhD Associate Professor, Department of Medicine, Boston University School of Medicine; Director of Thyroid Health Center, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Fellow, Association of Clinical Endocrinology

Stephanie L Lee, MD, PhD is a member of the following medical societies: American College of Endocrinology, American Thyroid Association, Endocrine Society

Disclosure: Nothing to disclose.

Admin

Hợp tác truyền thông, quảng cáo (0965.23.2222)